- Trials with a EudraCT protocol (3)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
3 result(s) found for: Cranial cavity.
Displaying page 1 of 1.
EudraCT Number: 2007-002445-20 | Sponsor Protocol Number: A8851009 | Start Date*: 2007-11-01 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE EFFICACY OF ANIDULAFUNGIN AND VORICONAZOLE IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF PROVEN OR PROBABLE INVASIVE AS... | |||||||||||||
Medical condition: INVASIVE ASPERGILLOSIS | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) NL (Ongoing) FR (Completed) GB (Completed) ES (Completed) IT (Completed) DE (Completed) CZ (Completed) BE (Completed) PT (Completed) GR (Completed) IE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021231-14 | Sponsor Protocol Number: A1501095 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE SAFETY, TOLERABILITY, AND EFFICACY OF VORICONAZOLE AND ANIDULAFUNGIN IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF INVA... | |||||||||||||
Medical condition: Primary therapy of invasive aspergillosis (IA) in pediatric subjects aged 2 to 17 years. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) FR (Ongoing) NL (Ongoing) DK (Prematurely Ended) PL (Completed) DE (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005275-10 | Sponsor Protocol Number: A1501080 | Start Date*: 2009-03-24 | |||||||||||||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||||||||||||
Full Title: A PROSPECTIVE, OPEN-LABEL, NON-RANDOMIZED, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF VORICONAZOLE AS PRIMARY THERAPY FOR TREATMENT OF INVASIVE ASPERGILLOSIS AND MOLDS SUCH AS... | |||||||||||||||||||||||
Medical condition: Treatment of proven or probable invasive aspergillosis (IA) and rare molds such as Scedosporium or Fusarium species. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) HU (Completed) CZ (Prematurely Ended) ES (Prematurely Ended) DE (Completed) BG (Prematurely Ended) Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
